Inhibrx director plans 500-share stock sale

Rule 144 notice for INBX discloses planned and recent 500‑share sales by a trust associated with director Kimberly Manhard.

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. (INBX) is the issuer for a Rule 144 notice filed on behalf of director Kimberly Manhard, covering planned sales of company common stock. The notice lists 500 shares of common stock to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $52,525.00 and 14,717,660 shares outstanding as of September 15, 2026.

The filing also reports that, during the prior three months, the Kimberly Joan Manhard Revocable Trust sold four blocks of 500 common shares each on September 8, 9, 11, and 14, 2026, for aggregate amounts of $57,570.00, $57,897.50, $55,887.50, and $55,130.00, respectively. The notice states that these sales occurred in the trust, of which Kimberly Manhard is a trustee.

Key Figures

Shares to be sold under Rule 144: 500 shares Aggregate market value of planned sale: $52,525.00 Shares outstanding: 14,717,660 shares +4 more

7 metrics

Shares to be sold under Rule 144 500 shares Planned sale of INBX common stock via Fidelity Brokerage Services LLC

Aggregate market value of planned sale $52,525.00 Value associated with the 500 shares to be sold

Shares outstanding 14,717,660 shares INBX common stock outstanding as of September 15, 2026

Sale on September 8, 2026 500 shares; $57,570.00 Common stock sold by Kimberly Joan Manhard Revocable Trust

Sale on September 9, 2026 500 shares; $57,897.50 Common stock sold by Kimberly Joan Manhard Revocable Trust

Sale on September 11, 2026 500 shares; $55,887.50 Common stock sold by Kimberly Joan Manhard Revocable Trust

Sale on September 14, 2026 500 shares; $55,130.00 Common stock sold by Kimberly Joan Manhard Revocable Trust

Key Terms

Rule 144, Open Market Purchase, aggregate market value, Revocable Trust

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Open Market Purchase financial

"Common | 08/28/2024 | Open Market Purchase | Issuer"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

aggregate market value financial

"500 | 52525.00 | 14717660 | 09/15/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Revocable Trust financial

"Kimberly Joan Manhard Revoc Trust 11025 N. Torrey Pines Road"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Inhibrx Biosciences, Inc. (INBX)?

It discloses a planned sale of 500 shares of INBX common stock under Rule 144, along with recent sales by the Kimberly Joan Manhard Revocable Trust, a trust associated with director Kimberly Manhard.

How many INBX shares are planned to be sold under this Rule 144 notice?

The notice covers a planned sale of 500 shares of Inhibrx Biosciences, Inc. common stock, with an aggregate market value listed as $52,525.00.

What recent INBX stock sales by the Manhard trust are reported?

The filing reports four sales of 500 common shares each by the Kimberly Joan Manhard Revocable Trust on September 8, 9, 11, and 14, 2026, for aggregate amounts of $57,570.00, $57,897.50, $55,887.50, and $55,130.00, respectively.

How many INBX shares are outstanding according to this notice?

The notice states that 14,717,660 shares of Inhibrx Biosciences, Inc. common stock were outstanding as of September 15, 2026.

Who is selling INBX shares in this Form 144 filing?

The filing is for sales attributable to Kimberly Manhard, a director of Inhibrx Biosciences, Inc., with sales occurring in the Kimberly Joan Manhard Revocable Trust, where she serves as trustee.

Through which broker and market will the INBX shares be sold?

The planned 500-share sale is to be executed through Fidelity Brokerage Services LLC, with the common stock listed for trading on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:02 PM Accepted by SEC EDGAR 09/15/2026 - 04:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001202094
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Inhibrx Biosciences, Inc.
SEC File Number	001-42031
Address of Issuer	11025 N. TORREY PINES ROAD, SUITE 140 LA JOLLA CALIFORNIA 92037
Phone	(858) 795-4220
Name of Person for Whose Account the Securities are To Be Sold	MANHARD KIMBERLY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	500	52525.00	14717660	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2024	Open Market Purchase	Issuer			500	08/28/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kimberly Joan Manhard Revoc Trust 11025 N. Torrey Pines Road Suite 140 La Jolla CA 92037	Common	09/08/2026	500	57570.00
Kimberly Joan Manhard Revoc Trust 11025 N. Torrey Pines Road Suite 140 La Jolla CA 92037	Common	09/09/2026	500	57897.50
Kimberly Joan Manhard Revoc Trust 11025 N. Torrey Pines Road Suite 140 La Jolla CA 92037	Common	09/11/2026	500	55887.50
Kimberly Joan Manhard Revoc Trust 11025 N. Torrey Pines Road Suite 140 La Jolla CA 92037	Common	09/14/2026	500	55130.00

144: Remarks and Signature

Remarks	Today's sale and sales from the past 3 months occurred in the Kimberly Joan Manhard Revoc Trust of which Kimberly Manhard is a trustee.
Date of Notice	09/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Kimberly Manhard.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)